The information highlighted (if any) are the most recent updates for this brand.
Hypersensitivity to the active substance or to any of the excipients listed in Description; Severe hepatic impairment (bilirubin >3 times upper limit of normal [ULN]; transaminases >10 times ULN); History of serious thrombosis with prior L-asparaginase therapy; History of pancreatitis, including pancreatitis related to previous L-asparaginase therapy (see Precautions); History of serious haemorrhagic events with prior L-asparaginase therapy (see Precautions).